person

Emmanuel D.

Country
France
Department
Nuclear Medicine

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
63
Sites with multiple studies

Has run more than one trial at 63 of 136 partner sites.

Specializations

Neuroendocrine Oncology

This investigator specializes in the treatment of neuroendocrine tumors, with particular expertise in thoracic manifestations affecting the lung and thymus. Their research encompasses the management of well to moderately differentiated neuroendocrine tumors requiring systematic therapeutic intervention.

  • Thoracic Neuroendocrine Tumors
  • Systemic Treatment Approaches
  • Tumor Differentiation Assessment

The investigator's work involves evaluating therapeutic responses through progression-free survival metrics and standardized assessment criteria.

Nuclear Medicine

The investigator focuses on advanced nuclear medicine applications, particularly Peptide Receptor Radionuclide Therapy (PRRT). Their expertise includes the implementation of radioisotope-based treatments for neuroendocrine conditions.

  • Radioligand Therapy
  • Therapeutic Radioisotopes
  • Treatment Response Assessment

Their research explores the therapeutic potential of targeted radiopharmaceuticals in oncological applications.

Comparative Therapeutics

The investigator studies the comparative effectiveness of different treatment modalities in neuroendocrine tumor management. Their work involves evaluating various therapeutic approaches to optimize patient outcomes.

  • Treatment Efficacy Analysis
  • Disease Progression Monitoring
  • Therapeutic Response Assessment

Their research contributes to establishing evidence-based treatment protocols for thoracic neuroendocrine tumors.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.